The suppressor of zest 12 (SUZ12), one of the core polycomb repressive complex 2 (PRC2) components, has increasingly appreciated as a key mediator during human tumorigenesis. However, its expression pattern and oncogenic roles in head and neck squamous cell carcinoma (HNSCC) remain largely unexplored yet. Here, we sought to determine its expression pattern, clinicopathological significance and biological roles in HNSCC. Through data mining and interrogation from multiple publicly available databases, our bioinformatics analyses revealed that SUZ12 mRNA was significantly overexpressed in multiple HNSCC patient cohorts. Moreover, SUZ12 protein was markedly up-regulated in primary HNSCC samples from our patient cohort as assessed by immunohistochemical staining and its overexpression significantly associated with cervical node metastasis and reduced overall and disease-free survival. In the 4-nitroquinoline 1-oxide (4NQO)-induced HNSCC mouse model, increased SUZ12 immunostaining was observed along with disease progression from epithelial hyperplasia to squamous cell carcinoma in tongue. Furthermore, shRNA-mediated SUZ12 knock-down significantly inhibited cell proliferation, migration and invasion in HNSCC cells, and resulted in compromised tumour growth in vivo. Collectively, our data reveal that SUZ12 might serve as a putative oncogene by promoting cell proliferation, migration and invasion, and also a novel biomarker with diagnostic and prognostic significance for HNSCC.
stage at diagnosis have been recognized as the key factors affecting patient prognosis. 3 Previous intensive efforts were made to unravel the genetic, epigenetic and environmental factors driving HNSCC tumorigenesis. 4 However, in-depth mechanistic understanding about HNSCC initiation and progression still remains far from complete.
Thus, development of effective treatment for HNSCC will largely hinge on the identification of genetic alterations and relevant molecular mechanisms during HNSCC carcinogenesis to find druggable targets of therapeutic values.
Epigenetic abnormality has been increasingly recognized as a hallmark of cancer and significantly contributes to cancer initiation and progression. 5 Until now, dozens of epigenetic modulators have been identified as pivotal mediators driving tumorigenesis and held great promise as therapeutic targets against cancer largely due to their pervasive roles as well as inherent reversible nature of epigenetic alternations. 6 Among these cancer-associated epigenetic modulators, polycomb group (PcG) proteins have stood out as essential participators of malignant transformation, metastatic spreading and promising targets for therapeutic intervention. 7 Mounting evidence has established that these PcG components commonly assemble into protein complexes with additional factors which are recruited to specific chromatin regions to maintain target genes in a transcriptionally repressive state. Briefly, two canonical PcG complexes (PRC1 and PRC2) harbour multiple core members to execute their functions by histone modifications. 8 As expected, our previous studies and others have provided strong evidence that multiple PcG members such as Bmi1 and EZH2 might function as bona fide oncogenes driving tumorigenesis in diverse sites and their elevated abundance associates with cancer aggressiveness and unfavourable prognosis in a myriad of human cancer including HNSCC. 7, [9] [10] [11] [12] [13] Recently, another
PcG member, suppressor of zest 12 (SUZ12), which is essential for PRC2-mediated gene silencing by generating trimethylation on lysine 27 residue of histone H3 (H3K27me3), has been increasingly appreciated as a putative oncogene or tumour suppressor underlying tumorigenesis. [14] [15] [16] SUZ12 has been found to be frequently overexpressed in several solid cancers including colorectal, ovarian and non-small lung cancer. Its aberrant overexpression significantly associated with aggressive clinicopathological features and inferior survival. 14, 17, 18 Furthermore, SUZ12 knock-down induced impaired tumour growth, invasion and metastasis in bladder, gastric and lung cancer. 17, 19, 20 However, on contrary, recurrent loss-of-function somatic alterations of SUZ12 have been identified in malignant peripheral nerve sheath tumour and contribute to its initiation and progression. 16 Therefore, these data highlight the complexity of biological roles of SUZ12 underlying tumorigenesis in diverse contexts.
However, to the best of our knowledge, the expression of SUZ12
and its clinicopathological significance in HNSCC have not been established yet.
In this study, we sought to investigate the expression of SUZ12
and its clinicopathological significance in primary human HNSCC samples and chemical-induced animal model. The tumorigenic roles of SUZ12 in HNSCC were also further explored both in vitro and in vivo. based on staining intensity and distribution using the immunoreactive score which was calculated as intensity score 9 proportion score as we reported previously. 9, 26 Intensity score was defined as 0, negative; 1, weak; 2, moderate; 3, strong. The proportion score was defined as 0, negative; 1, <10%; 2, 11%-50%; 3, 51%-80%; 4, >80% positive cells. Therefore, the total score ranged from 0 to 12.
| MATERIALS AND METHODS

| HNSCC patients and tissue samples
Accordingly, the immunoreactivity of each slide was categorized into three subgroups based on the final score: 0, negative; 1-4, low expression; 4-12, high expression, similar as our previous reports. Figure S1A , B, the abundance of SUZ12 mRNA was comparable without significant difference among patient groups stratified by pathological grade and clinical stage. In addition, there was no significant association between SUZ12 mRNA expression and patient overall survival (Kaplan-Meier analysis, logrank test, P = .773), when the median value of SUZ12 mRNA was employed as cut-off to stratify patients into low or high SUZ12-expressing groups ( Figure S2 ). 3.3 | SUZ12 overexpression positively associates with cervical node metastasis and overall survival
The detailed correlations between SUZ12 expression and the clinicopathological parameters in HNSCC are analysed and shown in F I G U R E 1 Overexpression of SUZ12 mRNA in multiple HNSCC cohorts. The mRNA levels of SUZ12 (log2-transformed) were compared between HNSCC samples and normal counterparts in multiple patient cohorts. (A-H) The original data were retrieved from Oncomine database and TCGA and then plotted using GraphPad Prism 6.0 software. Y-axis represents the median intensity, 25th and 75th percentile data. *P < .05; **P < .01; ns, not significant; Student's t test or Mann-Whitney U test as appropriate expression was found to be positively associated with the presence of cervical lymph nodes metastasis (P = .0329, Fisher's exact test).
To probe prognostic value of SUZ12 expression for patients with HNSCC, we next aimed to determine possible relationship 
| SUZ12 is involved in chemical-induced HNSCC tumorigenesis
Having revealed aberrantly high expression of SUZ121 in human HNSCC samples, we next developed a well-established chemicalinduced animal model to characterize the expression pattern of SUZ12 during HNSCC initiation and progression ( Figure 4A ). Pathological lesions were primarily identified in tongue following 4NQO treatment and displayed typical changes from epithelial hyperplasia, dysplasia, carcinoma in situ and invasive SCC, thus largely recapitulating the multiple-staged tumorigenic process in human HNSCC.
Furthermore, as shown in Figure 4B , immunohistochemical staining of SUZ12 in these samples indicated negative or low staining in normal tongue mucosa and epithelial with hyperplasia, while prominent strong nuclear staining in carcinoma in situ and invasive carcinoma. 
| SUZ12 knock-down inhibits proliferation, migration and invasion in HNSCC cells
Having revealed the overexpression of SUZ12 and its clinical significance in HNSCC, we next sought to dissect its oncogenic roles driving HNSCC initiation and progression by shRNA-mediated lossof-function approach. We designed and synthesized two independent shRNA sequences targeting human SUZ12 mRNA which were cloned into lentiviral vectors, sequenced and packaged. We The number in bold indicates statistical significance with P-values <.05.
marker Vimentin was down-regulated concomitant with E-cadherin up-regulation ( Figure 5G ).
To complement the in vitro loss-of-function assay in exploring pro-tumorigenic functions of SUZ12, we further performed bioinformatics analyses using TCGA-HNSCC data to identify the candidate genes whose expression was potentially correlated with SUZ12 which were subjected to gene ontology (GO) and pathway analyses.
A total number of 2606 SUZ12-related genes (1762 positive-related, 864 negative-related) in TCGA-HNSCC data were identified and subsequently subjected to GO/pathway analyses. As shown in Consistent with its primary roles as a chromatin modifier, most altered neighbours of SUZ12 were histone-related genes and PRC components. Notably, some well-established oncogenes such as DNMT1, 3 as well as JARID2 were also identified. Taken together, our in vitro cellular assay and bioinformatics assay both strongly favour the notion that SUZ12 is a novel putative oncogene in HNSCC.
F I G U R E 5 SUZ12 knock-down resulted in impaired cell proliferation, migration and invasion, while enhanced chemosensitivity to 5-FU. A, The knock-down efficiency of two shRNA lentiviral vectors targeting human SUZ12 was measured by Western blot. The shSUZ12-1 with higher knock-down potency was selected for the following experiments. Representative images of Western blot were shown from three independent experiments. B, Cell proliferation was determined after Cal27 and FaDu cells were infected with shSUZ12-1 lentivirus by MTT assay. C, D, Cell viability was probed in Cal27 (C) and FaDu (D) cells treated with shSUZ12-1 lentivirus and 5-FU alone or in combination for 48 h by MTT assay. E, Cell migration was determined in cells with stable SUZ12 knock-down by wound-healing assay. F, Cell invasion was determined in cells with stable SUZ12 knock-down by transwell invasion assay. Scale bar: 100 lm. G, The abundance of proliferative marker cyclin D1 and migration/invasion-relevant marker E-cadherin and Vimentin was compared in cells infected shSUZ12 lentivirus or control virus. Representative images of Western blot were shown from three independent experiments. # P > .05, *P < .05, **P < .01, Student's t test Figure 7E,F) . Moreover, the number of Ki67-positive cells was significantly reduced in tumour samples from SUZ12 knock-down cells as compared to samples formed from control cells ( Figure 7E,F) .
Together, these findings revealed that SUZ12 knock-down impaired tumour growth of HNSCC in vivo, suggesting that SUZ12 might be required for HNSCC growth.
| DISCUSSION
The epigenetic modifying complexes PRC1 and PRC2 regulate downstream targets by regulating chromatin structure and have been critically involved in multiple physiological and pathological processes including stem cell self-renewal and differentiation, cell apoptosis as well as tumorigenesis. 7, 34 Previous studies have suggested that SUZ12 might be a putative oncogene involving tumorigenesis and F I G U R E 6 Gene ontology and KEGG pathway analyses of SUZ12-related genes in HNSCC. A, GO biological process analyses of SUZ12 positively and negatively related genes identified from TCGA-HNSCC database. B, KEGG pathway analyses of SUZ12 positively and negatively related genes identified from TCGA-HNSCC database. C, Network formed by SUZ12 and its most frequently altered neighbour genes (50 of a total of 69) produced by cBioPortal platform serve as a potential diagnostic biomarker as well as anticancer therapeutic target. 14, 15, 17, 35 Accumulating evidence has indicated that SUZ12 is critically involved in tumorigenesis by promoting cell proliferation, migration and suppressing apoptosis. 14, 15, 17, 19 In line with this, our findings repression of E-cadherin and impaired invasiveness and metastasis. 15 Complementary, Herranz N and his colleagues revealed that the EMT master factor Snail interacted with SUZ12 and recruited PRC2 to the E-cadherin promoter, which in turn repressed E-cadherin expression and enhanced cancer metastasis. 37 In bladder cancer, SUZ12 was critically involved in TGF-b1-induced up-regulation of malat1, EMT and metastasis. 38 
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